Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Priveterra Acquisition Corp. Market Cap
The Priveterra Acquisition Corp. (PMGM) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered PMGM. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for PMGM is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedPMGM 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Priveterra Acquisition Corp. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PMGM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PMGM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2021
Staff Count
0
Country
United States
Sector/Industry
Financial Services/Shell Companies
CEO
Mr. Oleg Grodnensky
Market Cap
$97.5M
In 2023, PMGM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PMGM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 24 Jul 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The combined company's common stock will trade on the NYSE American under the symbol AEON, while warrants will trade under AEON WS.
Why It Matters - The listing of common stock and warrants on the NYSE American signals increased visibility and liquidity, potentially attracting more investors and impacting stock performance positively.
Fri, 21 Jul 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Priveterra Acquisition Corp. has completed its business combination with AEON Biopharma, a biopharmaceutical company preparing for Phase 3 trials of a proprietary neurotoxin.
Why It Matters - The successful business combination enhances Priveterra's growth potential and aligns with the biopharmaceutical sector's increasing interest, potentially driving stock value and investor interest.
Mon, 17 Jul 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Priveterra Acquisition Corp. (Nasdaq: PMGM) will become AEON Biopharma, Inc. and list its common stock and warrants on NYSE American post-business combination, authorized on July 13, 2023.
Why It Matters - Priveterra Acquisition Corp.'s transition to New AEON on NYSE American signifies increased visibility and credibility, potentially attracting more institutional investment and driving stock performance.
Tue, 11 Jul 2023
Sentiment - POSITIVE
Source - Market Watch
Summary - Priveterra Acquisition will list on the New York Stock Exchange after its business combination with AEON Biopharma.
Why It Matters - The planned NYSE listing of the combined company enhances visibility and credibility, potentially attracting more investors and driving stock performance.
Tue, 11 Jul 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Priveterra Acquisition Corp. (PMGM) plans to complete a business combination with AEON Biopharma, Inc., after which it will be renamed AEON Biopharma, Inc. AEON will become a wholly owned subsidiary.
Why It Matters - The business combination signals a strategic shift for Priveterra Acquisition Corp., potentially enhancing its market position and attracting investor interest in the biotech sector.
Fri, 30 Jun 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - AEON is seeking financing to complete a business combination and to support operations until key episodic migraine data is released.
Why It Matters - The need for financing indicates potential cash flow issues and reliance on data outcomes, which can significantly impact AEON's valuation and market confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
